|
|
|
Insider
Information: |
Bvf Inc/il |
Relationship: |
Indirect Beneficial Ow... |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
12 |
|
Direct
Shares |
49,829,941 |
|
Indirect Shares
|
136,880,248 |
|
|
Direct
Value |
$2,543,314,200 |
|
|
Indirect Value
|
$7,622,100,274 |
|
|
Total
Shares |
186,710,189 |
|
|
Total
Value |
$10,165,414,474 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
19
|
2
|
Stock
price went up :
|
18
|
0
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
18.0
|
-2.0
|
Percentage
Gain/Loss : |
64.8%
|
-200.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2010-04-12 |
5,041,447 |
2010-04-12 |
15,124,341 |
Premium* |
|
NPS Pharmaceuticals Inc |
NPSP |
Indirect Beneficial Ow... |
2008-03-11 |
0 |
2008-09-22 |
4,383,115 |
Premium* |
|
Astex Pharmaceuticals Inc |
ASTX |
Indirect Beneficial Ow... |
2008-05-01 |
0 |
2008-05-09 |
5,753,399 |
Premium* |
|
Neurobiological Technologies Inc |
NTII |
10% Owner |
2009-10-21 |
331,998 |
2009-10-21 |
995,994 |
Premium* |
|
Epirus Biopharmaceuticals Inc |
EPRS |
10% Owner |
2009-12-22 |
6,830,972 |
2009-12-22 |
20,492,916 |
Premium* |
|
Capstone Therapeutics Corp |
CAPS |
Indirect Beneficial Ow... |
2008-10-10 |
0 |
2008-10-14 |
5,136,888 |
Premium* |
|
Adolor Corp |
ADLR |
Indirect Beneficial Ow... |
2008-10-10 |
4,428,032 |
2008-10-31 |
6,214,551 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
10% Owner |
2009-09-10 |
4,278,851 |
2009-09-10 |
12,836,553 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
Indirect Beneficial Ow... |
2009-07-01 |
15,169,950 |
2009-07-01 |
45,509,850 |
Premium* |
|
Curis Inc |
CRIS |
Indirect Beneficial Ow... |
2009-02-03 |
8,921,716 |
2009-04-27 |
5,951,716 |
Premium* |
|
Repligen Corp |
RGEN |
Indirect Beneficial Ow... |
2009-07-07 |
2,765,050 |
2009-07-07 |
8,295,150 |
Premium* |
|
Gyre Therapeutics |
GYRE |
Indirect Beneficial Ow... |
2009-10-16 |
2,061,925 |
2009-10-16 |
6,185,775 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
195 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 8 of 8
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-07 |
4 |
B |
$3.81 |
$556,057 |
I/I |
146,100 |
4,482,215 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-10 |
4 |
B |
$3.73 |
$469,350 |
I/I |
126,000 |
4,608,215 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-11 |
4 |
B |
$3.71 |
$200,217 |
I/I |
53,900 |
4,662,115 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-12 |
4 |
B |
$3.82 |
$147,452 |
I/I |
38,600 |
4,700,715 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-13 |
4 |
B |
$3.77 |
$31,284 |
I/I |
8,300 |
4,709,015 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-14 |
4 |
B |
$3.84 |
$384,450 |
I/I |
100,000 |
4,809,015 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-17 |
4 |
B |
$3.80 |
$172,900 |
I/I |
45,500 |
4,854,515 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-03-19 |
4 |
B |
$3.90 |
$13,260 |
I/I |
3,400 |
4,857,915 |
1.5 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-09-19 |
4 |
S |
$8.55 |
$1,638,621 |
I/I |
(191,600) |
4,666,315 |
0 |
- |
|
NPSP |
NPS Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2008-09-22 |
4 |
S |
$8.72 |
$2,468,768 |
I/I |
(283,200) |
4,383,115 |
0 |
- |
|
NTII |
Neurobiological Technolog... |
Indirect Beneficial Owner |
|
2007-11-06 |
4 |
B |
$2.43 |
$114,083 |
I/I |
47,000 |
4,938,393 |
1.5 |
- |
|
NTII |
Neurobiological Technolog... |
Direct Beneficial Owner |
|
2009-10-21 |
4 |
S |
$0.91 |
$4,191,819 |
D/D |
(4,606,395) |
331,998 |
0 |
- |
|
RGEN |
Repligen Corp |
Indirect Beneficial Owner |
|
2009-07-06 |
4 |
S |
$5.52 |
$2,486,478 |
D/D |
(450,800) |
2,766,050 |
0 |
- |
|
RGEN |
Repligen Corp |
Indirect Beneficial Owner |
|
2009-07-07 |
4 |
S |
$5.50 |
$5,500 |
D/D |
(1,000) |
2,765,050 |
0 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-06-18 |
4 |
B |
$1.45 |
$1,602,623 |
I/I |
1,105,257 |
4,209,574 |
1.5 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-07-08 |
4 |
B |
$2.99 |
$245,799 |
I/I |
82,100 |
4,291,674 |
1.5 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-07-09 |
4 |
B |
$3.04 |
$2,434,112 |
I/I |
800,300 |
5,091,974 |
1.5 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-07-10 |
4 |
B |
$3.03 |
$1,221,615 |
I/I |
403,200 |
5,495,174 |
1.5 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-07-11 |
4 |
B |
$3.07 |
$38,373 |
I/I |
12,500 |
5,507,674 |
1.5 |
- |
|
SGXP |
Sgx Pharmaceuticals, Inc. |
Indirect Beneficial Owner |
|
2008-08-20 |
4 |
D |
$3.00 |
$16,523,022 |
I/I |
(5,507,674) |
0 |
0 |
- |
|
195 Records found
|
|
Page 8 of 8 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|